Daily Current Affairs Quiz : February 5, 2022

Notes:
The National Heritage City Development and Augmentation Yojana (HRIDAY), a central sector scheme was launched in 2015 and was implemented in 12 cities.
As many as 77 projects have been implemented with an outlay of Rs 453.90 crores. 2 projects amounting to Rs 18.34 crore- Project in Badami (Karnataka) and Project in Warangal (Telangana) are under implementation. The mission period ended in 2019.

Notes:
Punaura Dham located in Bihar has been included in the Ramayana circuit of Swadesh Darshan Scheme. It has been recently included under PRASHAD Scheme of the Ministry of Tourism.
Bihar has several tourist places in the scheme including Thirthankar Circuit in Vaishali- Arrah- Masad- Patna- Rajgir- Pawapuri- Champapuri, Spiritual Circuit at Sultanganj – Dharmshala – Deoghar and Buddhist circuit at Bodh Gaya.

Notes:
US President Joe Biden announced a relaunch of the “Cancer Moonshot” program started during the Obama administration.
The program was launched with the goal of ending Cancer that kills more than 600,000 people a year in the U.S. The revamped initiative aims to reduce the death rate from cancer by at least 50 percent over the next 25 years. The President also announced a campaign to get more people screened for cancer.

Notes:
Telangana launched Mission Bhagiratha in 2015 to make drinking water sources safe and sustainable.
Several districts of the state are hard-rock terrains with minimum rainfall. The fluoride content in groundwater is higher than permissible levels. The scheme addressed these issues by constructing around 50 water treatment plants (WTP) across the state. The state has been tapping water from various reservoirs, projects and river flows, from the basins of Krishna and Godavari.

Notes:
Chimeric antigen receptor, CAR – T-cell therapy works by genetically engineering an individual’s T-cells to recognise and destroy cancer cells.
T-cells are a type of white blood cell of the immune system that can recognise and destroy foreign cells. Two first human patients who were treated with the therapy still possess cancer-killing cells a decade later. In the UK the therapy is approved for use in children, young adults and adults for certain types of blood cancers.